Sarepta Therapeutics (SRPT) Higher on Barron's Mention
Tweet
Share
E-mailGet Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (Nasdaq: SRPT) continues its recent ramp following a positive piece in Barron's over the weekend highlighting the company's treatment for Duchenne muscular dystrophy.
While shares are up from $4 to $10 recently, analysts argue they could go as high as $26 as peak sales of eteplirsen "could conservatively reach $600 million in the U.S. alone."
Shares are up 8 percent in pre-open trading Monday.
While shares are up from $4 to $10 recently, analysts argue they could go as high as $26 as peak sales of eteplirsen "could conservatively reach $600 million in the U.S. alone."
Shares are up 8 percent in pre-open trading Monday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- Holcim said to acquire part of James Hardie's EU business
- Hunterbrook bullish on Modine Manufacturing (MOD)
Create E-mail Alert Related Categories
Momentum Movers, Trader TalkRelated Entities
Barron'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
